BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 31102069)

  • 21. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma.
    Heider U; von Metzler I; Kaiser M; Rosche M; Sterz J; Rötzer S; Rademacher J; Jakob C; Fleissner C; Kuckelkorn U; Kloetzel PM; Sezer O
    Eur J Haematol; 2008 Feb; 80(2):133-42. PubMed ID: 18005386
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Design, Synthesis, and Structure-Activity relationships of Evodiamine-Based topoisomerase (Top)/Histone deacetylase (HDAC) dual inhibitors.
    Zhu F; Meng X; Liang H; Sheng C; Dong G; Liu D; Wu S
    Bioorg Chem; 2022 May; 122():105702. PubMed ID: 35286923
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Valproic acid enhances tubulin acetylation and apoptotic activity of paclitaxel on anaplastic thyroid cancer cell lines.
    Catalano MG; Poli R; Pugliese M; Fortunati N; Boccuzzi G
    Endocr Relat Cancer; 2007 Sep; 14(3):839-45. PubMed ID: 17914112
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Panobinostat induces apoptosis via production of reactive oxygen species and synergizes with topoisomerase inhibitors in cervical cancer cells.
    Wasim L; Chopra M
    Biomed Pharmacother; 2016 Dec; 84():1393-1405. PubMed ID: 27802904
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Proteasome inhibition sensitizes non-small cell lung cancer to histone deacetylase inhibitor-induced apoptosis through the generation of reactive oxygen species.
    Denlinger CE; Rundall BK; Jones DR
    J Thorac Cardiovasc Surg; 2004 Nov; 128(5):740-8. PubMed ID: 15514602
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Potential anti-cancer effect of N-hydroxy-7-(2-naphthylthio) heptanomide (HNHA), a novel histone deacetylase inhibitor, for the treatment of thyroid cancer.
    Kim SM; Park KC; Jeon JY; Kim BW; Kim HK; Chang HJ; Choi SH; Park CS; Chang HS
    BMC Cancer; 2015 Dec; 15():1003. PubMed ID: 26698299
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anti-tumor effect of evodiamine by inducing Akt-mediated apoptosis in hepatocellular carcinoma.
    Yang F; Shi L; Liang T; Ji L; Zhang G; Shen Y; Zhu F; Xu L
    Biochem Biophys Res Commun; 2017 Mar; 485(1):54-61. PubMed ID: 28189683
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents.
    Xue K; Gu JJ; Zhang Q; Mavis C; Hernandez-Ilizaliturri FJ; Czuczman MS; Guo Y
    J Cancer Res Clin Oncol; 2016 Feb; 142(2):379-87. PubMed ID: 26314218
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dual inhibition of HDAC and EGFR signaling with CUDC-101 induces potent suppression of tumor growth and metastasis in anaplastic thyroid cancer.
    Zhang L; Zhang Y; Mehta A; Boufraqech M; Davis S; Wang J; Tian Z; Yu Z; Boxer MB; Kiefer JA; Copland JA; Smallridge RC; Li Z; Shen M; Kebebew E
    Oncotarget; 2015 Apr; 6(11):9073-85. PubMed ID: 25940539
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Histone Deacetylase Inhibitor, Trichostatin A, Synergistically Enhances Paclitaxel-Induced Cytotoxicity in Urothelial Carcinoma Cells by Suppressing the ERK Pathway.
    Hsu FS; Wu JT; Lin JY; Yang SP; Kuo KL; Lin WC; Shi CS; Chow PM; Liao SM; Pan CI; Hong JY; Chang HC; Huang KH
    Int J Mol Sci; 2019 Mar; 20(5):. PubMed ID: 30866433
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
    Pei XY; Dai Y; Grant S
    Clin Cancer Res; 2004 Jun; 10(11):3839-52. PubMed ID: 15173093
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synergistic inhibition of thyroid cancer by suppressing MAPK/PI3K/AKT pathways.
    Kandil E; Tsumagari K; Ma J; Abd Elmageed ZY; Li X; Slakey D; Mondal D; Abdel-Mageed AB
    J Surg Res; 2013 Oct; 184(2):898-906. PubMed ID: 23602735
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy on anaplastic thyroid carcinoma of valproic acid alone or in combination with doxorubicin, a synthetic chenodeoxycholic acid derivative, or lactacystin.
    Kim TH; Yoo YH; Kang DY; Suh H; Park MK; Park KJ; Kim SH
    Int J Oncol; 2009 May; 34(5):1353-62. PubMed ID: 19360347
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Suppression of AKT Potentiates Synergistic Cytotoxicity of Apigenin with TRAIL in Anaplastic Thyroid Carcinoma Cells.
    Kim SH; Kang JG; Kim CS; Ihm SH; Choi MG; Yoo HJ; Lee SJ
    Anticancer Res; 2015 Dec; 35(12):6529-37. PubMed ID: 26637867
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Berberine and Evodiamine Act Synergistically Against Human Breast Cancer MCF-7 Cells by Inducing Cell Cycle Arrest and Apoptosis.
    Du J; Sun Y; Lu YY; Lau E; Zhao M; Zhou QM; Su SB
    Anticancer Res; 2017 Nov; 37(11):6141-6151. PubMed ID: 29061795
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combined effects of all-trans-retinoic acid and trichostatin A on the induction of differentiation of thyroid carcinoma cells.
    Yuan GB; Kuang AR; Fan Q; Yu LB; Mi YX
    Chin J Cancer; 2010 Apr; 29(4):379-84. PubMed ID: 20346212
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Novel histone deacetylase inhibitors in the treatment of thyroid cancer.
    Mitsiades CS; Poulaki V; McMullan C; Negri J; Fanourakis G; Goudopoulou A; Richon VM; Marks PA; Mitsiades N
    Clin Cancer Res; 2005 May; 11(10):3958-65. PubMed ID: 15897598
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gefitinib inhibition of drug resistance to doxorubicin by inactivating ABCG2 in thyroid cancer cell lines.
    Lopez JP; Wang-Rodriguez J; Chang C; Chen JS; Pardo FS; Aguilera J; Ongkeko WM
    Arch Otolaryngol Head Neck Surg; 2007 Oct; 133(10):1022-7. PubMed ID: 17938326
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The histone deacetylase inhibitor MS-275 interacts synergistically with fludarabine to induce apoptosis in human leukemia cells.
    Maggio SC; Rosato RR; Kramer LB; Dai Y; Rahmani M; Paik DS; Czarnik AC; Payne SG; Spiegel S; Grant S
    Cancer Res; 2004 Apr; 64(7):2590-600. PubMed ID: 15059916
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Synergistic cytotoxicity effect of histone deacetylase inhibitor combined with paclitaxel on lung cancer cell lines and its mechanism].
    Zhang D; Liu CT; Yu XD; Liu Y
    Ai Zheng; 2009 Dec; 28(12):1270-6. PubMed ID: 19958621
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.